Avoro Capital Advisors’s Genocea Biosciences, Inc. GNCA Stock Holding History

Avoro Capital Advisors’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-5,084,184	Closed	-$86K	–	42
2022 Q2	$86K	Hold	5,084,184	–	–	﹤0.01%	40
2022 Q1	$6.36M	Hold	5,084,184	–	–	0.12%	43
2021 Q4	$5.9M	Hold	5,084,184	–	–	0.1%	39
2021 Q3	$9.76M	Hold	5,084,184	–	–	0.15%	43
2021 Q2	$11.9M	Hold	5,084,184	–	–	0.21%	40
2021 Q1	$13.8M	Hold	5,084,184	–	–	0.24%	39
2020 Q4	$12.3M	Hold	5,084,184	–	–	0.21%	38
2020 Q3	$11.6M	Buy	+5,084,184	New	+$13.3M	0.17%	41

Other funds holding GNCA

AICPI

ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Avoro Capital Advisors's GNCA Position: Q3 2022 in Review

Avoro Capital Advisors sold out of Genocea Biosciences, Inc. (GNCA) in Q3 2022, closing a stake of 5,084,184 shares — an estimated $86K sold.

Avoro Capital Advisors first reported a position in GNCA in Q3 2020 and held it in 8 quarters. The position peaked at $13.8M in Q1 2021. 1 fund tracked by Wall St. Rank holds GNCA as of Q3 2022.

Avoro Capital Advisors reported no remaining Genocea Biosciences, Inc. position as of Q3 2022 after selling out during the quarter.
Avoro Capital Advisors sold 5,084,184 Genocea Biosciences, Inc. shares in Q3 2022, an estimated $86K.
Avoro Capital Advisors first reported a position in Genocea Biosciences, Inc. in Q3 2020 and held it in 8 quarters.
Avoro Capital Advisors's Genocea Biosciences, Inc. position peaked at $13.8M in Q1 2021.
1 fund tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q3 2022.

Based on Avoro Capital Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.